Neuvivo
About:
Neuvivo is a late clinical-stage biopharmaceutical company developing a new ALS treatment.
Website: https://www.neuvivo.com/
Top Investors: Primestreet Group
Description:
Neuvivo is a private, late-clinical stage biopharmaceutical company committed to creating and delivering advanced treatments for ALS and other neurodegenerative diseases.
Total Funding Amount:
$11M
Estimated Revenue Range:
$1M to $10M
Headquarters Location:
Palo Alto, California, United States
Founded Date:
2020-01-01
Founders:
Ari Azhir
Number of Employees:
11-50
Last Funding Date:
2023-06-15
IPO Status:
Private
Industries:
© 2025 bioDAO.ai